Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C

Journal of Hepatology

Volumn 34, Issue 5, 2001, Pages 740-747

  Caballero, Trinidad ^a   Pérez Milena, Alejandro ^a   Masseroli, Marco ^a   O'Valle, Francisco ^a   Salmerón, Francisco J ^b   Del Moral, Raimundo M G ^a   Sánchez Salgado, Guillermo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Automatic quantification; Hepatitis C; Image analysis; Interferon; Knodell activity index; Knodell fibrosis scoring; Liver fibrosis; Scheuer activity grade; Scheuer fibrosis staging

Indexed keywords

ALPHA2 INTERFERON; RECOMBINANT INTERFERON;

ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DEVICE; DISEASE ACTIVITY; DRUG EFFECT; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT OUTCOME; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; BIOPSY; FEMALE; FIBROSIS; HEPATITIS C, CHRONIC; HISTOLOGICAL TECHNIQUES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTERFERON TYPE I, RECOMBINANT; LIVER; MALE; TREATMENT OUTCOME;

EID: 0342467854     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(01)00006-X     Document Type: Article

References (30)

1. Shindo M., Di Bisceglie A.M., Cheung L., Shilh W.K., Crisitano K., Feinstone S.M., et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 115:1991;700-704.
2. Okanoue T., Itoh Y., Minami M., Sakamoto S., Yasui K., Sakamoto M., et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol. 30:1999;653-659.
3. Reichard O., Glaumann H., Fryden A., Norkrans G., Wejstal R., Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol. 30:1999;783-787.
4. Lindsay K.L. Therapy of hepatitis C: overview. Hepatology. 26(Suppl 1):1997;71S-77S.
5. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 339:1998;1493-1499.
6. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
7. Kaserer K., Fiedler R., Steindl P., Müller C.H., Wrba F., Ferenci P. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. Histopathology. 32:1998;454-461.
8. Davis G.L., Balart L.A., Shiff E.R., Lindsay K., Bodenheimer H.C., Perrillo R.P., et al. Treatment of chronic hepatitis C with recombinant human alpha-interferon: a multicenter randomized, controlled trial. N Engl J Med. 321:1989;1501-1506.
9. Di Bisceglie A.M., Martin P., Kassianides C., Lisker-Melman M., Murray L., Waggoner J., et al. Recombinant interferon alpha therapy for chronic hepatitis C: randomized, double-bind, placebo-controlled trial. N Engl J Med. 321:1989;1506-1510.
10. David E., Pucci A., Palladin D., Saracco G., Garello E., Pintus C., et al. Histologic changes in liver biopsy specimens produced by recombinant interferon-alpha 2b therapy for chronic non-A, non-B viral hepatitis. Am J Clin Pathol. 98:1992;397-401.
11. Tsubota A., Kumada H., Chayama K., Arase Y., Saitoh S., Koida I., et al. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection. J Hepatol. 27:1997;49-55.
12. Camps J., Castilla A., Ruíz J., Civeira M.P., Prieto J. Randomized trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol. 17:1993;390-396.
13. Hiramatsu N., Hayashi N., Kasahara A., Hagiwara H., Takehara T., Haruna Y., et al. Improvement on liver fibrosis in chronic hepatitis C patients treated with natural interferon-alpha. J Hepatol. 22:1995;135-142.
14. Masseroli M., Caballero T., O'Valle F., Del Moral R.M.G., Pérez-Milena A., Del Moral R.G. Automatic quantification of liver fibrosis: design and validation of a new image analysis method. Comparison with semi-quantitative indexes of fibrosis. J Hepatol. 32:2000;453-464.
15. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplawitz N., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
16. Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 13:1991;372-374.
17. Craxï A., Cammà C., Giunta M. Definition of response to antiviral therapy in chronic hepatitis C. J Hepatol. 31(Suppl 1):1999;160-167.
18. Bianchi L., Gudat F. MacSween R.N.M., Anthony P.P., Scheuer P.J., Burt A.D., Portmann B.C. Pathology of the liver. 3rd ed :1994;349-395 Churchill Livingstone, Edinburgh, UK.
19. Batts K.P., Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 19:1995;1409-1417.
20. Ludwig J. The nomenclature of chronic active hepatitis: an obituary. Gastroenterology. 105:1993;274-278.
21. Sweat F., Puchtler H., Rosenthal S.I. Sirius red F3BA as a stain for connective tissue. Arch Pathol. 78:1964;69-72.
22. Manabe N., Chevalier M., Chossegros P., Causse X., Guerret S., Trépo C., et al. Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology. 18:1993;1344-1349.
23. Guèchot J., Lonia A., Sefartty L., Giral P., Giboudeau J., Poupon R. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effects of alpha-interferon therapy. J Hepatol. 22:1995;22-26.
24. Pilette C., Rousselet M.C., Bedossa P., Chappard D., Oberti F., Rifflet H., et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs. semi-quantitative scores. Comparison with serum markers. J Hepatol. 28:1998;439-446.
25. Balkwill F.R. Peptide regulatory factors. Interferons. Lancet. 1:1989;1060-1063.
26. Hautekeete M.L., Geerts A. The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch. 430:1997;195-207.
27. Gressner A.M. Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Kidney Int. 49(Suppl 54):1996;S39-S45.
28. Duchatelle V., Marcellin P., Giostra E., Bregeaud L., Pouteau M., Boyer N., et al. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method. J Hepatol. 29:1998;20-28.
29. Sakaida I., Nagatomi A., Hironaka K., Uchida K., Okita K. Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy. Am J Gastroenterol. 94:1999;489-496.
30. Chevallier M., Guerret S., Chossegros P., Gerard F., Grimaud J.A. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology. 20:1994;349-355.